Clinical trial
Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With…
NCT00083304 · Spectrum Pharmaceuticals, Inc, Industry · Completed
Key facts
| NCT number | NCT00083304 |
|---|---|
| Title | Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast Cancer |
| Official title | A Phase 3 Randomized, Open-label Comparative Study of Standard Whole Brain Radiation Therapy With Supplemental Oxygen, With or Without Concurrent RSR13 (Efaproxiral), in Women With Brain Metastases From Breast Cancer |
| Acronym | ENRICH |
| Lead sponsor | Spectrum Pharmaceuticals, Inc, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer, Metastases |
| Intervention type | Drug, Other, Radiation |
| Interventions | Efaproxiral, Whole Brain Radiation Therapy (WBRT), Supplemental Oxygen |
| Enrollment | 368 |
| Start date | Feb 1, 2004 |
| Primary completion | Jun 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | May 19, 2004 |
| Last update posted | May 10, 2013 |
| Countries | Argentina, Austria, Brazil, Canada, Chile, Croatia, France, Greece, Hungary, Italy, Lithuania, Peru and 3 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: